Status:
COMPLETED
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
Lead Sponsor:
Johns Hopkins University
Conditions:
Maculopathy, Age-Related
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Brief Summary
The purpose of this study is to determine the sensitivity of the optical coherence tomography (OCT) test in detecting neovascular AMD in eyes at high risk for CNV development. In order to test this hy...
Detailed Description
Primary Objective: The purpose of this study is to determine the sensitivity of the OCT in detecting conversion to neovascular AMD by two years in eyes at high risk for CNV, with FA serving as the go...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age 50 years or greater
- Best corrected visual acuity letter score = 65 or greater (approximate Snellen equivalent of 20/50 or better in the candidate study eye)
- Neovascular AMD in the fellow eye and no CNV in the candidate study eye (absence of CNV confirmed by FA which will be graded in a masked fashion by the AMD DOC Study Reading Center)
- Candidate study eye must have evidence of at least one large druse (≥ 125µm) and focal hyperpigmentation within 3600μm of the fovea and visible on color fundus photography, red-free photograph, or fluorescein angiography
- Participant must have media clear enough in the candidate study eye to permit fundus photography, fluorescein angiography, and optical coherence tomography and absence of any fluorescein allergies
- Results of the baseline PHP and supervised Amsler grid will not affect eligibility of the participant. Subjects can be eligible for further follow-up even if they have positive PHP and Amsler grid
- Eligible participants who have a positive PHP or supervised Amsler grid for that eye at the initial screening visit should have a second PHP or supervised Amsler grid screening visit within 2 weeks in order to repeat the PHP or Amsler test or the participant may repeat the PHP or Amsler grid that day before pupillary dilation. Participants with a 2nd positive PHP or supervised Amsler grid are still eligible for further follow-up
- All tests (supervised Amsler grid, PHP, OCT, FA) must be performed within 2 weeks of each other
- Participants with non-foveal geographic atrophy in the candidate study eye are still eligible for enrollment in the study
Exclusion
- Known allergy to fluorescein angiography or allergic reaction during screening
- Advanced AMD with CNV in both eyes confirmed on FA graded by the AMD DOC Study Reading Center
- Foveal geographic atrophy in the study eye
- Positive OCT test for the candidate study eye, as read by the AMD DOC Study Reading Center, for subretinal fluid, intraretinal edema, or retinal thickening that falls within the top 1% of the normative data base for the Stratus OCT
- Significant media opacity that precludes reasonable quality retinal imaging including color fundus photographs, fluorescein angiography, or OCT in the candidate study eye to assess the presence of CNV
- Evidence of macular disease (e.g., pattern dystrophy, diabetic macular edema, vitreomacular traction) other than AMD in the study eye
- Previous surgical or laser treatment to the macula of the study eye
- Diabetic retinopathy
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00417846
Start Date
January 1 2007
End Date
August 1 2009
Last Update
October 5 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Vitreous Associates
Beverly Hills, California, United States, 90211
2
The Wilmer Eye Institute at Johns Hopkins
Baltimore, Maryland, United States, 21287
3
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
4
Retina Associates of Cleveland
Beachwood, Ohio, United States, 44122